1. Home
  2. SCYX vs GIFT Comparison

SCYX vs GIFT Comparison

Compare SCYX & GIFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • GIFT
  • Stock Information
  • Founded
  • SCYX 1999
  • GIFT 1999
  • Country
  • SCYX United States
  • GIFT United States
  • Employees
  • SCYX N/A
  • GIFT N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • GIFT Catalog/Specialty Distribution
  • Sector
  • SCYX Health Care
  • GIFT Consumer Discretionary
  • Exchange
  • SCYX Nasdaq
  • GIFT Nasdaq
  • Market Cap
  • SCYX 34.9M
  • GIFT 33.9M
  • IPO Year
  • SCYX 2014
  • GIFT N/A
  • Fundamental
  • Price
  • SCYX $1.10
  • GIFT $1.10
  • Analyst Decision
  • SCYX
  • GIFT Strong Buy
  • Analyst Count
  • SCYX 0
  • GIFT 1
  • Target Price
  • SCYX N/A
  • GIFT $4.00
  • AVG Volume (30 Days)
  • SCYX 204.1K
  • GIFT 21.4K
  • Earning Date
  • SCYX 11-05-2025
  • GIFT 11-12-2025
  • Dividend Yield
  • SCYX N/A
  • GIFT N/A
  • EPS Growth
  • SCYX N/A
  • GIFT N/A
  • EPS
  • SCYX N/A
  • GIFT N/A
  • Revenue
  • SCYX $3,257,000.00
  • GIFT $90,569,384.00
  • Revenue This Year
  • SCYX $422.61
  • GIFT $5.90
  • Revenue Next Year
  • SCYX $240.56
  • GIFT $13.45
  • P/E Ratio
  • SCYX N/A
  • GIFT N/A
  • Revenue Growth
  • SCYX N/A
  • GIFT 8.55
  • 52 Week Low
  • SCYX $0.66
  • GIFT $0.82
  • 52 Week High
  • SCYX $1.66
  • GIFT $3.86
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 71.20
  • GIFT 53.52
  • Support Level
  • SCYX $0.81
  • GIFT $1.01
  • Resistance Level
  • SCYX $1.31
  • GIFT $1.12
  • Average True Range (ATR)
  • SCYX 0.07
  • GIFT 0.08
  • MACD
  • SCYX 0.03
  • GIFT 0.01
  • Stochastic Oscillator
  • SCYX 58.33
  • GIFT 40.72

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About GIFT RDE Inc. Common Stock

Giftify Inc through its wholly-owned subsidiary, has been in the business of connecting digital consumers, businesses and communities with dining and merchant deal options throughout the United States. The company connects digital consumers, businesses, and communities offering dining and merchant deal options nationwide restaurants, and retailers to customers. The Company buys merchant gift cards from the general public and distributors at a discount and then resells them at a markup.

Share on Social Networks: